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Abstract 
Background: The US FDA recently developed CD3+, a counterfeit detection tool that is based on sample illumina-
tion at specific wavelengths of light and visual comparison of suspect sample and packaging materials to an authen-
tic sample. To test performance of the CD3+ in field conditions, a study was conducted in Ghana which compared 
the CD3+ side-by-side with two existing medicine quality screening technologies—TruScan™ Portable Raman 
spectrometer and GPHF Minilab®.
Methods: A total of 84 anti-malarial test samples comprising artemether–lumefantrine tablets and artesunate–amo-
diaquine tablets were used. The technologies were evaluated for sensitivity in determining counterfeit/substandard 
(The term counterfeit or falsified is used in this article to refer to medicines that carry a false representation of identity 
or source or both. The term substandard is used to refer to medicines that do not meet the quality specifications 
given in the accepted pharmacopeia.) medicines, specificity in determining authentic products, and reliability of the 
results. Authentic samples obtained from manufacturers were used as reference standards. HPLC analysis data was 
used as the “gold standard” for decisions regarding a sample being authentic or substandard/counterfeit.
Results: CD3+ had a sensitivity of 1.00 in detecting counterfeit/substandard products compared to Minilab (0.79) 
and TruScan (0.79). CD3+ had a lower specificity (0.53) in determining authentic products compared to the specifici-
ties reached by Minilab (0.99) and TruScan (1.00). High sensitivity in this context means that the technology is effective 
in identifying substandard/counterfeit products whereas the low specificity means that the technique can sometimes 
mischaracterize good products as substandard/counterfeit. Examination of dosage units only (and not packaging) 
using CD3+ yielded improved specificity 0.64. When only assessment of sample identification was done, the TruScan 
provided sensitivity (1.00) and specificity (0.99); and the Minilab provided sensitivity (1.00) and specificity (1.00). All 
three technologies demonstrated 100 % reliability when used to analyse the same set of samples over 3 days by a 
single analyst and also when used to determine the same set of samples by three different analysts. Eight of the field 
samples were confirmed to be counterfeits with no active pharmaceutical ingredient content. All three technologies 
identified these samples as counterfeits.
Conclusions: The study revealed the relative effectiveness of the technologies as quality control tools. Using a com-
bination of CD3+, with either the Minilab or TruScan, to screen for medicine quality will allow for complete examina-
tion of both the dosage units and the packaging to decide whether it is authentic or counterfeit.
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Background
The proliferation of counterfeit and substandard medi-
cines has been a major concern to the global public health 
community. Medicine quality survey studies, particularly 
for anti-malarial medicines, have shown prevalence rate 
of counterfeit and substandard medicines ranging from 
20  % to as high as 64  % [1–3]. Similar studies on qual-
ity of anti-tuberculosis and anti-retroviral medicines also 
revealed the extent of the problem of counterfeits and 
substandard products [4, 5]. Counterfeit and substandard 
anti-infective medicines pose a threat to public health 
and their prevalence has been linked to treatment fail-
ure, increased mortality and morbidity, and emergence of 
drug resistance [6, 7].
Preventing the circulation of counterfeit and substand-
ard medicines has become a great challenge especially 
in countries with limited resources. In many developing 
countries, the national quality control laboratory of the 
medicines regulatory authority lacks the capacity to fully 
evaluate the quality of medicines on the market, usually 
due to the lack of equipment, personnel, and infrastruc-
ture needed for quality control testing. To help ameliorate 
the situation, particularly in resource-limited countries, 
a number of simple, non-sophisticated, and affordable 
medicine quality screening tools have been used or intro-
duced for use in screening the quality of medicines. The 
use of the screening tools reduces the number of sam-
ples that a national medicines quality control laboratory 
must test, which subsequently reduces the burden on the 
national laboratory and its limited resources [8].
Two commonly used field-based screening tools are the 
Global Pharma Health Fund (GPHF) Minilab1 which is 
based on thin-layer chromatography and the TruScan2 
hand-held Raman spectrometer from Thermo Scientific, 
which is based on Raman spectroscopy.
The United States Food and Drug Administration (US 
FDA) recently developed a counterfeit detection tool 
known as the CD3+. The tool is based on sample illumi-
nation at specific wavelengths of light and visual compar-
ison of suspect packaging materials and dosage form to 
an authentic sample [9]. To test the performance of the 
CD3+ in field conditions, US FDA collaborated with the 
US Pharmacopeial Convention (USP) to conduct a field 
study in Ghana.
In the study, side-by-side comparison of CD3+ with two 
existing screening tools was performed on field samples 
(samples acquired in the markets of Ghana) to obtain an 
1 The GPHF Minilab is a trademarked property of the Global Pharma 
Health Fund (GPHF).
2 The Thermo Scientific TruScan RM analyzer is a trademarked property of 
Thermo Fisher Scientific Inc.
understanding of the sensitivity3, specificity4, and reliability5 
associated with the use of these technologies. The study used 
commonly available anti-malarial medicines in Ghana to 
investigate the unique advantages of these screening tools.
The specific objectives of the study were as follows:
Objective 1 Evaluate the sensitivity and specificity of 
the US FDA CD3+, the GPHF Minilab, and the Thermo 
Scientific TruScan hand-held Raman spectrometer in 
Ghana as counterfeit/substandard detection tools for two 
commonly used artemisinin-based combination therapy 
(ACT) medicines—artemether–lumefantrine (AR-LU) 
and artesunate–amodiaquine (AS-AQ)—for the treat-
ment of malaria in sub-Saharan Africa.
Objective 2 Evaluate the reliability of CD3+ to detect 
substandard and counterfeit medicines and compare it to 
the reliability of the GPHF Minilab and TruScan Raman 
hand-held spectrometer.
Objective 3 Establish the comparative advantages and 
disadvantages of the three field based technologies.
Methods
Development of authentic libraries
Authentic samples of the anti-malarial products used 
in the study were sourced directly from their respective 
manufacturers (Table  1) and stored under conditions 
specified on the labelling. The CD3+ Authentic Image 
Library (CDAIL) was developed at the US FDA’s Forensic 
Chemistry Center (FCC). The CDAIL consisted of white 
light images of dosage forms and packaging, quadrant 
images of the packaging for printing process analysis, 
and images of the dosage forms and packaging at all the 
wavelengths and filter combinations featured on the tool. 
The Raman authentic spectral library for the TruScan 
was developed by the Promoting the Quality of Medi-
cines (PQM) staff at USP headquarters using the authen-
tic samples. In the case of GPHF Minilab analyses, the 
authentic samples were used as reference standards as 
Minilab does not have a library feature.
Field samples
Through the Promoting the Quality of Medicines (PQM) 
programme, funded by the United States Agency for Inter-
national Development and implemented by USP, sentinel 
sites had been established in Ghana and five of these sentinel 
3 Sensitivity is defined in this study as the proportion of medicines that are 
detected as substandard/counterfeit by the tool out of all the tablets that 
are substandard/counterfeit. It is the probability that the tool will correctly 
detect substandard/counterfeit anti-malarial tablets.
4 Specificity is the proportion of anti-malarial tablets that are identified as 
authentic by the tool out of all the tablets that are of authentic quality. It is 
the probability that the tool will correctly identify good quality anti-malarial 
tablets.
5 Reliability is the ability of the tool to produce the same results with 
repeated measurements.
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sites served as sample collection and field testing stations for 
this study. The field samples were collected by staff from the 
Ghana Food and Drugs Authority (Ghana FDA) at the sentinel 
sites located in the cities of Accra (ACC), Kumasi (KSI), Tako-
radi (TAK), Ho, and Bolgatanga (BOL), using convenience 
sampling—a non-probability sampling approach where sam-
ples that are the easiest to access are collected and collection 
areas are strategically selected. Field sample testing using the 
CD3+ and the GPHF Minilab were performed at these study 
sites. All other analyses, including HPLC analyses of field 
samples and authentic samples, TruScan Raman analyses, 
and other study testing activities, took place at USP’s Center 
for Pharmaceutical Advancement and Training (CePAT), a 
USP Global Health Impact Program located in Accra, Ghana. 
TruScan Raman analyses were not done in the field because 
there were insufficient units of the tool for all the study sites.
HPLC analyses of authentic and field samples
HPLC analyses of authentic samples and field samples 
were performed and the results were used as the gold 
standard to judge all results obtained with the three 
screening tools. The HPLC procedures were sourced 
from the USP Medicines Compendium [10] and from a 
published article [11] and complete verification of the 
analytical methods were done before using the proce-
dures. The HPLC analysis was based on analysis of the 
dosage unit only, since packaging and labelling could 
not be evaluated by this technique. The tests performed 
were identification and assay of the content of active 
pharmaceutical ingredients (API). The procedures used 
were not specific for determination of impurities asso-
ciated with the APIs in the medicines; hence, impurity 
levels of the samples were not determined.
Assessment of objective 1: sensitivity and specificity 
experiments
A total of 84 samples were used for the evaluation of 
the sensitivity and specificity of the three technologies 
(Table 2). This consisted of field samples, authentic sam-
ples, counterfeit samples, and authentic samples that had 
been stressed at 40 °C/75 % RH for 4 weeks in a stability 
chamber.
For CD3+ evaluation, the packaging material (primary 
and secondary packaging, and labelling), the printing on 
the packaging material, and the dosage units were visu-
ally examined at various wavelength/filter combinations 
to determine if the observed images were consistent with 
the library images of the authentic sample. Conclusions 
regarding whether or not a sample was consistent with 
the authentic were based on the results of all three exam-
inations—packaging print, packaging material, and dos-
age unit.
In the case of GPHF Minilab testing, thin layer chro-
matography (TLC) analysis [12] of each sample was con-
ducted using the corresponding authentic sample as the 
reference standard. The retardation factor (RF) values and 
intensities of the spots on the TLC plate—for the sample 
and the authentic product—were used to make decisions 
regarding identity and drug content of the sample. Pass 
or fail decisions were based on the results of both the 
identification and content analyses.
For the TruScan Raman analyses, the spectrometer was 
used to measure a Raman spectrum of the sample and 
the measured Raman spectrum was compared6 to that of 
the authentic Raman reference spectrum in the library. A 
pass decision was obtained based on statistical consist-
ency (p > 0.05) of the sample spectrum with that of the 
authentic.
CD3+: use of library images
Study samples were compared with images in the CDAIL 
to determine if the sample images were consistent with 
(CW) or not consistent with (NCW) the library images, 
which is pass or fail.
6 TruScan Raman spectrometers utilize an embedded decision engine con-
taining proprietary algorithms for the comparison.
Table 1 Authentic samples used in the study
AR–LU Artemether and Lumefantrine
Product Manufacturer Strength (mg) # of lots
Coartem (AR-LU) tablets Novartis 20/120 5
Coartem dispersible tablets Novartis 20/120 5
Artemether-Lumefantrine tablets Ipca 20/120 4
Lumerax (AR-LU) tablets Ipca 40/240 2
Winthrop Artesunate-Amodiaquine Amodiaquine tablets Sanofi-Aventis 50/135 5
Winthrop Artesunate-Amodiaquine Amodiaquine tablets Sanofi-Aventis 100/270 5
Artesunate-Amodiaquine tablets Ipca 50/135 3
Artesunate-Amodiaquine tablets Ipca 100/270 3
Total 32
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CD3+: use of side‑by‑side image comparison
Samples were sent to the participants without their 
knowledge that the samples were authentic (“blind sam-
ples”), and the participants were asked to determine 
whether the samples were authentic or not. The blind 
sample study indicated that some authentic samples were 
flagged as not consistent with (NCW) the CDAIL. This 
prompted USP to setup another method of comparison 
by using side-by-side comparison of authentic and field 
sample. Thus, in addition to the library image compari-
son in the blind sample study, CePAT staff performed 
side-by-side comparisons of images of blind samples 
with that of a physical authentic sample to investigate if 
the use of library images alone contributed to the NCW 
results reported for authentic samples by the study sites.
Evaluation of the ability of the technologies to distinguish 
between different strengths of a product
Tests were performed to determine the ability of the 
screening technologies to distinguish between products 
presented in different strengths as reflected by API con-
tent. For this evaluation, the following authentic sam-
ples were used: AS-AQ (50/135  mg)(Sanofi, Maphar, 
Morocco), AS-AQ (100/270  mg)(Sanofi, Maphar, 
Morocco), AR-LU (20/120  mg)(Ipca Laboratories Ltd., 
India), AR-LU (40/240 mg) (Ipca Laboratories Ltd., India).
CD3+, GPHF Minilab, and TruScan analyses of the 
AS-AQ (50/135  mg) “sample” were performed using 
the higher strength product—AS-AQ (100/270  mg)—as 
the reference product. Results from the tools indicating 
whether or not the sample was consistent with the ref-
erence product were documented. These analyses were 
repeated, the second time using the higher strength 
product as “sample” and the lower strength product as 
“reference.” The two AR-LU samples were similarly ana-
lysed using the three technologies.
Assessment of objective 2: reliability experiments
Reliability of results from the three technologies were 
assessed using samples consisting of three lots each of 
select AR-LU and AS-AQ authentic samples, samples 
stressed at 40 °C/75 % RH for 4 weeks, and counterfeit sam-
ples received from the Ghana FDA (Table 3). Three analysts 
each performed CD3+ analysis, GPHF Minilab analysis, 
and TruScan Raman analysis on all of these samples. One 
of the analysts repeated the test daily on three different 
days. The ability of each tool to give the same results with 
these repeated measurements was determined.
Results and discussions
Objective 1 results: sensitivity and specificity
Sensitivity and specificity, in this study, are measures 
of how well a screening technology performs when it is 
compared to the “gold standard”—HPLC—in detecting 
counterfeit and authentic anti-malarial tablets. Sensitivity 
provides the probability that the technology will correctly 
detect a substandard/counterfeit product. Specificity, on 
the other hand, provides the probability that the technol-
ogy will correctly identify a authentic product.
The sensitivity of a screening technology was calcu-
lated as the ratio of the total number of samples that are 
detected as substandard/counterfeit by the technology to 
the total number of samples that are substandard/coun-
terfeit as determined by HPLC. The specificity was cal-
culated as the ratio of the total number of samples that 
are identified as authentic by the technology to the total 
number of samples that are authentic as determined by 
HPLC.
Table 2 Breakdown of test samples used to evaluate sensitivity and specificity of three technologies
a Ipca’s Artesunate-Amodiaquine tablets were not on the market at the time of the study
Product Manufacturer Field samples Additional samples Total
Accra Bolga HO Kumasi Takoradi Counter–FEIT Authentic Stressed
Artemetheter-Lumefantrine tablets, 
20/120 mg
Ipcaa 0 1 0 3 1 0 0 0 5
Lumerax (Artemether + Lumefantrine tab-
lets, 40/240 mg)
Ipca 2 0 0 4 5 0 0 0 11
Coartem (Artemether + Lumefantrine tab-
lets, 20/120 mg)
Novartis 2 4 3 3 2 3 0 0 17
Coartem dispersible (Artemether + Lumefan-
trine tablets, 20/120 mg)
Novartis 4 0 3 0 3 0 3 1 14
Winthrop (Artesunate + Amodiaquine tab-
lets, 50/135 mg)
Sanofi-Aventis 8 5 1 1 10 0 3 1 29
Winthrop (Artesunate + Amodiaquine tab-
lets, 100/270 mg)
Sanofi-Aventis 1 3 1 0 3 0 0 0 8
Total 17 13 8 11 24 3 6 2 84
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Sensitivity and specificity of CD3+
CD3+ analysis (packaging print, packaging material, and 
dosage unit visual examination) identified all the samples 
that were substandard/counterfeit (sensitivity  =  1.00); 
however, the specificity in identifying authentic medi-
cines was only 0.53 (Table 4). Considering that the “gold 
standard”, HPLC analysis, was based on only the dosage 
unit, and not on both the dosage unit together with the 
package information, the study also looked at the speci-
ficity and sensitivity of the CD3+ when only the dos-
age unit was examined with the tool; that is, excluding 
the CD3+ packaging examination. The results shown 
in Table 5 indicate an improvement of the specificity to 
0.64; the sensitivity remained unchanged at 1.00.
The data for CD3+ analysis of blind samples that was per-
formed to establish that the study participants were correctly 
using the CD3+ tool is shown in Table 6. Data from the four 
study sites (BOL, HO, KSI, and TAK) that participated in this 
study shows only 30  % “consistent with” (CW) results for the 
authentic samples. Based on the high (70  %) NCW results 
reported by the study sites, even for the authentic samples, 
CePAT performed an investigation to determine if the use of 
CDAIL library images contributed to the results. Using the same 
samples, CePAT staff compared CD3+ analyses using only 
library images against analyses using a side-by-side comparison 
of images of the authentic sample captured at the time the sam-
ple was being analysed. The CePAT data is shown in Table 6. The 
specificities calculated based on the CePAT data were 0.2 using 
library images and 1.00 using the side-by-side comparison. This 
limited data suggests using side-by-side comparison rather than 
the image library may help improve the specificity of CD3+ in 
determining authentic anti-malarial medicines.
It is important to note that although the CD3+ iden-
tified authentic products as counterfeit the tool did not 
identify counterfeit products as authentic. It has also 
been noted by the US FDA (unpublished data) that as 
users become more experienced with using the CD3+ 
and CDAIL overtime, this increased experience has 
shown an improvement in the specificity of CD3+.
Sensitivity and specificity of the GPHF Minilab
GPHF Minilab analysis (based on TLC identification and 
estimation of content) identified all the authentic anti-
malarial samples (specificity =  1.00), and the sensitivity 
in determining substandard/counterfeit products was 
0.79 (Table 7). Separate treatment of the data to extract 
information that compared TLC identification with 
HPLC identification data showed that the GPHF Minilab 
had sensitivity (1.00) and specificity (1.00) when used 
only for identification (Table 8).
Sensitivity and specificity of the TruScan Raman spectrometer
The sensitivity and specificity data obtained for the TruS-
can Raman spectrometer compared to HPLC identifica-
tion and assay data were very similar to that of the GPHF 
Minilab, 0.79 and 0.99, respectively (Table 9). Comparison 
of the TruScan Raman data to HPLC identification only 
Table 3 List of samples used to evaluate reliability of three 
technologies
a These samples were obtained from the Ghana FDA and had previously been 
tested and confirmed to be counterfeit
b Samples stressed at 40 °C/75 % RH for 4 weeks. HPLC analysis showed there 
were no significant changes in the content of the active ingredients of the 
stressed samples
Sample type Sample name Strength (mg) # of lots
Authentic Coartem tablets 20/120 1







Counterfeita Coartem tablets 20/120 3





Table 4 Sensitivity and  specificity data for  CD3+  analysis 






 Counterfeit/substandard 14 33










 Counterfeit/substandard 14 25
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data, however, showed sensitivity (1.00) and specificity 
(0.99) for the TruScan Raman spectrometer (Table 10).
Counterfeit field samples7
Eight of the field samples collected from the study sites were 
confirmed by HPLC analyses to be counterfeits with zero (or 
almost zero) active pharmaceutical ingredient (API) content. 
7 Information about these counterfeit medicines were provided to the 
Ghana FDA.
These samples comprised seven counterfeit Coartem tablets 
samples and one counterfeit Ipca artemether–lumefantrine 
(20/120  mg) tablet sample. All three technologies—CD3+, 
GPHF Minilab, and TruScan Raman spectrometer—identi-
fied these eight samples as counterfeits.
Evaluation of the ability of the technologies to distinguish 
between different strengths of a product
The results of tests performed to determine the ability 
of the screening tools to distinguish between products 
Table 6 Comparison of CD3+ analysis of blind (authentic) samples using library images versus using side-by-side com-
parison of the blind sample and authentic product
CW consistent with (authentic); NCW Not consistent with (counterfeit/substandard)
a Side-by-side comparison of images of sample to that of the physical authentic sample
Authentic sample Study sites
Based on library images Side-by-side comparisona
BOL HO KSI TAK CePAT CePAT
Coartem-D CW NCW NCW NCW CW CW
Coartem CW NCW NCW CW NCW CW
Lumerax 40/240 NCW NCW NCW NCW NCW CW
Winthrop 50/135 CW NCW NCW CW NCW CW
Winthrop 100/270 NCW NCW NCW CW NCW CW
Table 7 Sensitivity and  specificity data for  GPHF Minilab 






 Counterfeit/substandard 11 0
 Authentic 3 70
Sensitivity Specificity
0.79 1.00
Table 8 Sensitivity and  specificity data for  GPHF Minilab 





 Counterfeit/substandard 11 0
 Authentic 0 73
Sensitivity Specificity
1.00 1.00






 Counterfeit/substandard 11 1
 Authentic 3 69
Sensitivity Specificity
0.79 0.99





 Counterfeit/substandard 11 1
 Authentic 0 72
Sensitivity Specificity
1.00 0.99
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presented in different strengths is provided in Table 11. 
The data shows the CD3+  and GPHF Minilab clearly 
determined the two products compared in each case 
were different, whereas the TruScan did not distinguish 
between these products as shown by the erroneous “pass” 
results. The results provide an indication of the capabil-
ity of these tools to identify substandard products having 
a lower or a higher amount of active ingredient(s) than 
what is claimed. This suggests that the TruScan may be 
inadequate in detecting certain substandard medicines; 
hence further studies need to be done to truly assess 
the Raman spectrometer’s ability to detect substandard 
medicines.
Objective 2 results: reliability
Reliability is the ability of a tool to produce the same 
results with repeated measurements. In this study, three 
analysts each obtained the same set of conclusions for 
the 11 samples used to evaluate reliability of the three 
tools—CD3+, GPHF Minilab, and TruScan Raman ana-
lyzer. Also, one analyst obtained consistent conclusions 
for all three tools when analyses of the 11 samples were 
repeated on three different days for each technology. The 
reliability of CD3+, GPHF Minilab, and TruScan Raman 
technologies was each determined to be 100  % in this 
study.
Object 3 results: comparative advantages 
and disadvantages
One objective of the study was to compare the advan-
tages and disadvantages of the three field-based screen-
ing techniques and establish complementary advantages 
in using more than one tool. CD3+ complements the vis-
ual inspection test which is a requirement for medicine 
quality evaluation. It is the only technology that provides 
comprehensive examination of printing style, packag-
ing, and dosage unit and, hence, could be used in concert 
with other screening technologies to improve detection 
of counterfeit and substandard products. CD3+ results 
however, are user dependent, as the user decides whether 
sample image is consistent with that of the reference 
product. The user’s decision can be improved if side-
by-side comparison (e.g. suspect and authentic tablets) 
is used for analysis rather than comparison to an image 
from library and as users become more experienced with 
using the CD3+ and CDAIL overtime. Compared to 
Minilab and TruScan, CD3+ has the relative advantage 
of being significantly less expensive, portable as a hand-
held tool, easy to learn and operate, and can be used to 
screen both dosage unit and packaging.
The TruScan Raman spectrometer was found to be very 
robust, as the pass/fail decisions were user independent. 
The tool demonstrated high sensitivity and high specific-
ity for identification—but did not distinguish between 
products having as much as 50 % difference in API con-
tent. This shows that additional studies may be warranted 
to determine the technology’s ability to detect substand-
ard medicines.
The GPHF Minilab uses a low-cost technology—TLC—
that uses standards under the same conditions as the 
sample during testing. The technique has wide applica-
tion and can be used for a wide range of active ingredi-
ents and does not need the development of a library of 
authentic product. The GPHF Minilab demonstrated 
high specificity in determining authentic products. Using 
it as an identification only tool, the GPHF Minilab dem-
onstrated high sensitivity and specificity. TLC results, 
however, may be influenced by the user, especially when 
used for drug content or assay estimation.
Using combination of CD3+, with either the Minilab 
or TruScan, to screen for medicine quality will allow for 
complete examination of both the dosage units and the 
packaging information in addition to assessment of other 
quality attributes leading to a detailed view of the prod-
uct to decide whether it is authentic or counterfeit.
Conclusions
The study revealed the CD3+ is very effective in identi-
fying counterfeit products as well as in identifying dif-
ferences in strength of a given product. The technology 
Table 11 Performance of CD3+, TruScan Raman, and GPHF Minilab in distinguishing between different strengths
AS-AQ Artesunate and Amodiaquine fixed-dose combination tablets
AR-LU Artemether and Lumefantrine fixed dose combination tablets
a Fail Sample is not consistent with reference product (different)
b Pass Sample is consistent with reference product (identical)
Brand name Manufacturer Sample composition/strength Reference product CD3+ (dosage) TruScan raman GPHF minilab
Winthrop Sanofi AS-AQ 50/135 AS-AQ, 100/270 mg, Sanofi Faila Passb Fail
Winthrop Sanofi AS-AQ 100/270 AS-AQ, 50/135 mg, Sanofi Fail Pass Fail
Lumerax Ipca AR-LU 40/240 AR-LU, 20/120 mg, Ipca Fail Pass Fail
AR-LU 20/120 Ipca AR-LU 20/120 AR-LU, 40/240 mg, Ipca Fail Pass Fail
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is also unique in that it allows for the visual inspection 
of both the packaging information and the dosage unit 
and can detect very subtle differences in the packaging 
and dosage unit. Comparing authentic images side by 
side with samples seems to improve the detection ability 
of the technology than using library images. Addition-
ally, one of the strengths of the technology is conducting 
real-time screening of large numbers of same items very 
quickly, once the product is determined to be authentic 
or counterfeit.
The Minilab which is based on TLC and the TruS-
can based on Raman spectroscopy are also powerful in 
determining the identity of the API in the product but 
do not have the ability to assess packaging information. 
Minilab cannot be relied upon to determine falsification 
of product brands. The TruScan also showed limited abil-
ity to detect differences in strength of the same product 
whereas the Minilab and the CD3+ were effective in 
detecting differences in strength of dosage unit as meas-
ured by API content.
The comparative advantages of the three technologies 
are captured in Fig. 1—these relative advantages referred 
to as the effectiveness index in the Figure, is the abil-
ity of the techniques to assess various quality attributes 
including:
  • Identity of the active pharmaceutical ingredient(s);
  • Identity of the product brand, that is, whether or not a 
product is falsified; and,
  • Determination of the API content (“strength”).
Using the tools in unison presents an excellent oppor-
tunity to assess various quality attributes of the medicine 
and increases the chance of detecting counterfeit and 
substandard medicines.
Challenges and limitations
The CD3 Authentic Image Library (CDAIL) products 
were from three manufacturers (Table 1). The use of tar-
geted manufacturers and products represents a straight-
forward application of the CD3 technology; however, 
during the development of the CDAIL for this project, it 
was noted that some of the authentic products presented 
challenges. For instance, the packaging of the authentic 
products from one manufacturer displayed inconsist-
encies/differences in the packaging information for the 
same product. While these variations were included in 
the CDAIL, it raised concerns how to account for these 
inconsistencies/differences to ensure that all variations in 
the authentic packaging information of a given product 







































Fig. 1 Relative effectiveness of CD3+, TruScan, GPHF minilab, and HPLC as medicine quality control tools. Key *Deceptive API, #Deceptive product, 
+API content
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Another challenge encountered during the study was 
the number of different presentations of packaging and 
labelling for the same product. For example, a total of 176 
anti-malarial field samples that were supposed to match 
the authentic samples acquired from the manufacturer 
were collected at the five study sites. Of these, only 73 
field samples were used for the study, as visual exami-
nation of the remaining samples showed the packaging 
and labelling differed significantly from the authentic 
samples. The CD3+ library was generated using specific 
authentic samples; field samples that were clearly differ-
ent from the authentic products were not used so as not 
to bias the study.
It was observed that manufacturers of the anti-malarial 
products presented several variations of their packaging 
and labelling—in some cases to provide for different lan-
guages, packaging for different age groups, packaging for 
multiple-dose versus unit dose, and, in one instance, even 
different marketing logos or manufacturer names for a 
company that appeared to be transitioning from one logo 
to another. This presents a major challenge in identifying 
authentic products by CD3+ because the packaging and 
labelling information were varied in very subtle ways that 
were not captured in the library. This should be a major 
concern particularly for regulatory authorities, as it sug-
gests authentic products with a high degree of packaging 
variability present opportunities for counterfeits to enter 
the legitimate supply chain. If the manufacturers would 
standardize their packaging it would provide for a more 
secure supply chain. Manufacturers need to standardize 
packaging to ensure secure supply chain.
Also, insufficient units of the TruScan for all field sites 
precluded actual field sample testing using this tool, 
hence TruScan testing of all samples was performed at a 
single study site.
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